{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:19:56Z","timestamp":1791652796097,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203930\/B\/16\/Z"],"award-info":[{"award-number":["203930\/B\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower\u2010cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes and associated psychosocial variables in a group of patients undergoing a nonmedical switch to biosimilar adalimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with inflammatory bowel disease (IBD) were followed before and after switching from Humira to Amgevita. Objective disease activity was assessed pre\u2010 and post\u2010switch using the Harvey\u2013Bradshaw Index (Crohn's disease) or partial Mayo score (ulcerative colitis), faecal calprotectin and C\u2010reactive protein. Subjective symptom burden was measured using the IBD Control Questionnaire (IBDCQ). Pre\u2010switch, health anxiety was measured using the Health Anxiety Index (HAI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 64 patients aged 18\u201367 were enrolled. IBDCQ scores marginally improved post\u2010switch (13.33\n                      <jats:italic>vs<\/jats:italic>\n                      , 12.49,\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u00a0.043), with no significant changes in objective disease activity scores, faecal calprotectin or C\u2010reactive protein. Sixteen patients reported 17 new adverse events within 4\u00a0weeks. Logistic regression revealed a significant relationship between HAI scores and adverse events (\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u00a0.0079); each unit increase in HAI score increased the odds of reporting an adverse event by 21%. Drug cost savings for the 64 patients over 8\u00a0weeks totalled \u20ac143\u2009958.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching to biosimilar adalimumab did not affect disease control or quality of life. 25% of patients developed new side effects, particularly those with high levels of health anxiety. Significant cost savings were achieved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70086","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:44:13Z","timestamp":1745973853000},"page":"2628-2635","source":"Crossref","is-referenced-by-count":4,"title":["A single\u2010centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease"],"prefix":"10.1002","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-036X","authenticated-orcid":false,"given":"Louise","family":"Rabbitt","sequence":"first","affiliation":[{"name":"Discipline of Pharmacology and Therapeutics, School of Medicine University of Galway  Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ine","family":"Keogh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Galway University Hospitals  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Duane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Galway University Hospitals  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ferguson","sequence":"additional","affiliation":[{"name":"School of Mathematical and Statistical Sciences University of Galway  Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hobbins","sequence":"additional","affiliation":[{"name":"Research Ireland Centre for Medical Devices (C\u00daRAM, 13\/RC\/2073_P2)  Ireland"},{"name":"Health Economics &amp; Policy Analysis Centre (HEPAC), Institute for Lifecourse &amp; Society (ILAS) University of Galway  Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"McGuire","sequence":"additional","affiliation":[{"name":"School of Psychology &amp; Centre for Pain Research University of Galway  Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Research Ireland Centre for Medical Devices (C\u00daRAM, 13\/RC\/2073_P2)  Ireland"},{"name":"Health Economics &amp; Policy Analysis Centre (HEPAC), Institute for Lifecourse &amp; Society (ILAS) University of Galway  Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence J.","family":"Egan","sequence":"additional","affiliation":[{"name":"Discipline of Pharmacology and Therapeutics, School of Medicine University of Galway  Ireland"},{"name":"Department of Gastroenterology Galway University Hospitals  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102012\u2010303376"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.014"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102016\u2010210459"},{"key":"e_1_2_10_5_1","unstructured":"\u201cMedicines Management Programme.\u201d Best\u2010value biological medicines: Adalimumab & Etanercept.https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/medicines-management\/best-value-medicines\/best-value-biological-medicines\/"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17525"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744\u2010022\u201000465\u20106"},{"key":"e_1_2_10_8_1","volume-title":"State of health in the EU","author":"OECD","year":"2021"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010021\u201001243\u20100"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01372"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e3182294a50"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e3182738826"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001282"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.10.952"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1037\/hea0000416.supp"},{"issue":"1","key":"e_1_2_10_16_1","first-page":"133","article-title":"Nonspecific medication side effects and the nocebo phenomenon","volume":"10","author":"Barsky AJ","year":"2004","journal-title":"Sci Eng Ethics"},{"key":"e_1_2_10_17_1","unstructured":"\u201cCentral Sstatistics Office.\u201dCoverage of Essential Health Services.https:\/\/www.cso.ie\/en\/releasesandpublications\/ep\/p-sdg3\/irelandsunsdgs2019-reportonindicatorsforgoal3goodhealthandwell-being\/healthcare\/"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102013\u2010305600"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjad147"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010018\u20100690\u2010x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(80)92767\u20101"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/08870449908407311"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291702005822"},{"key":"e_1_2_10_25_1","unstructured":"HIQA.Guidelines for the economic evaluation of health Technologies in Ireland 2020. Published Online2020:108.https:\/\/www.hiqa.ie\/sites\/default\/files\/2020-09\/HTA-Economic-Guidelines-2020.pdf"},{"key":"e_1_2_10_26_1","unstructured":"Department of Health.1 February and 1 June 2022 Consolidated pay scales. Health Sector Consolidated Salary Scales in Accordance with the FEMPI Acts the Public Service Agreements and the Public Service Pay and Pensions Act 2017.2022. Accessed November 1 2022.https:\/\/healthservice.hse.ie\/staff\/pay\/pay-scales\/"},{"key":"e_1_2_10_27_1","unstructured":"\u201cCentral Statistics Office.\u201dConsumer Price Index \u2010 CSO.https:\/\/www.cso.ie\/en\/statistics\/prices\/consumerpriceindex\/"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15541"},{"key":"e_1_2_10_29_1","unstructured":"HSE Primary Care Reimbursement Service. Product Updates Notification \u2010 G.M.S. Reimbursable Items.https:\/\/www.sspcrs.ie\/libr\/html\/monthlyproductupdate.pdf"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010023\u201002712\u2010w"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010023\u201000616\u20103"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.05.025"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac092"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1590\/s0004\u20102803.202000000\u201045"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010018\u20102418\u20104"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102019\u2010034183"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510738"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2022.110719"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102016\u2010210742"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)30068\u20105"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab100"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70086","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:34:04Z","timestamp":1775630044000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/bcp.70086"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70086","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}